Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
- PMID: 33296010
- PMCID: PMC8182874
- DOI: 10.1007/s00467-020-04874-z
Correction to: The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab
Erratum for
-
The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.Pediatr Nephrol. 2021 Apr;36(4):889-898. doi: 10.1007/s00467-020-04774-2. Epub 2020 Oct 13. Pediatr Nephrol. 2021. PMID: 33048203 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
